Navin Pinto1, Arlene Naranjo2, Emily Hibbitts2, Susan G Kreissman3, M Meaghan Granger4, Meredith S Irwin5, Rochelle Bagatell6, Wendy B London7, Emily G Greengard8, Julie R Park1, Steven G DuBois9. 1. Seattle Children's Hospital, Seattle, WA, USA; University of Washington School of Medicine, Seattle, WA, USA. 2. COG Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, FL, USA. 3. Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. 4. Department of Hematology/Oncology, Cook Children's Hospital, Fort Worth, Texas, USA. 5. Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. 6. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 7. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA. 8. University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA. 9. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA. Electronic address: steven_dubois@dfci.harvard.edu.
Abstract
BACKGROUND: Induction chemotherapy plays an important role in the management of patients with high-risk neuroblastoma. Predictors of response to induction therapy are largely lacking. We sought to describe clinical and biological features associated with induction response. METHODS: Patients from four consecutive COG high-risk trials were included. Response was evaluated by the 1993 International Neuroblastoma Response Criteria. The primary end-point was end-induction partial response (PR) or better. Univariate analyses were performed to compare response as a function of clinical or biologic predictors. A multivariate logistic regression model using significant predictors from univariate analyses was constructed to model PR or better. RESULTS: The analytic cohort included 1242 patients. End-induction response ≥PR was significantly associated with higher event-free and overall survival. Baseline factors associated with ≥PR included age <18 months (87.4% with ≥PR vs. 78.7% if older; p = 0.0103), International Neuroblastoma Staging System non-stage 4 (89.0% vs. 78.4% if stage 4; p = 0.0016), MYCN amplification (85.5% vs. 77.1% if non-amplified; p = 0.0006), 1p loss of heterozygosity (LOH; 85.6% vs. 76.0% if no LOH; p = 0.0085), no 11q LOH (84.8% vs. 70.9% if 11q LOH; p = 0.0004) and high mitosis-karyorrhexis index (MKI; 84.5% vs. 77.5% if low-intermediate MKI; p = 0.0098). On multivariable analysis (n = 407), the absence of 11q LOH was the only factor that remained significantly associated with ≥PR (odds ratio: 1.962 vs. 11q LOH; 95% confidence interval 1.104-3.487; p = 0.0216). CONCLUSIONS: Improved end-induction response in high-risk neuroblastoma is associated with longer survival. Patients with 11q LOH are less likely to respond to induction therapies and should be prioritised for novel approaches in future trials.
BACKGROUND: Induction chemotherapy plays an important role in the management of patients with high-risk neuroblastoma. Predictors of response to induction therapy are largely lacking. We sought to describe clinical and biological features associated with induction response. METHODS:Patients from four consecutive COG high-risk trials were included. Response was evaluated by the 1993 International Neuroblastoma Response Criteria. The primary end-point was end-induction partial response (PR) or better. Univariate analyses were performed to compare response as a function of clinical or biologic predictors. A multivariate logistic regression model using significant predictors from univariate analyses was constructed to model PR or better. RESULTS: The analytic cohort included 1242 patients. End-induction response ≥PR was significantly associated with higher event-free and overall survival. Baseline factors associated with ≥PR included age <18 months (87.4% with ≥PR vs. 78.7% if older; p = 0.0103), International Neuroblastoma Staging System non-stage 4 (89.0% vs. 78.4% if stage 4; p = 0.0016), MYCN amplification (85.5% vs. 77.1% if non-amplified; p = 0.0006), 1p loss of heterozygosity (LOH; 85.6% vs. 76.0% if no LOH; p = 0.0085), no 11q LOH (84.8% vs. 70.9% if 11q LOH; p = 0.0004) and high mitosis-karyorrhexis index (MKI; 84.5% vs. 77.5% if low-intermediate MKI; p = 0.0098). On multivariable analysis (n = 407), the absence of 11q LOH was the only factor that remained significantly associated with ≥PR (odds ratio: 1.962 vs. 11q LOH; 95% confidence interval 1.104-3.487; p = 0.0216). CONCLUSIONS: Improved end-induction response in high-risk neuroblastoma is associated with longer survival. Patients with 11q LOH are less likely to respond to induction therapies and should be prioritised for novel approaches in future trials.
Authors: W B London; R P Castleberry; K K Matthay; A T Look; R C Seeger; H Shimada; P Thorner; G Brodeur; J M Maris; C P Reynolds; S L Cohn Journal: J Clin Oncol Date: 2005-08-22 Impact factor: 44.544
Authors: H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald; D O Stram; R B Gerbing; J N Lukens; K K Matthay; R P Castleberry Journal: Cancer Date: 1999-07-15 Impact factor: 6.860
Authors: Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544
Authors: Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Howard M Katzenstein; Susan L Cohn; Richard M Shore; Dianna M E Bardo; Paul R Haut; Marie Olszewski; Jennifer Schmoldt; Dachao Liu; Alfred W Rademaker; Morris Kletzel Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544
Authors: Katherine K Matthay; Veronique Edeline; Jean Lumbroso; Marie Laure Tanguy; Bernard Asselain; Jean Michel Zucker; Dominique Valteau-Couanet; Olivier Hartmann; Jean Michon Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Andrew D J Pearson; C Ross Pinkerton; Ian J Lewis; John Imeson; Caroline Ellershaw; David Machin Journal: Lancet Oncol Date: 2008-03 Impact factor: 41.316
Authors: H Ikeda; T Iehara; Y Tsuchida; M Kaneko; J Hata; H Naito; M Iwafuchi; N Ohnuma; H Mugishima; Y Toyoda; M Hamazaki; J Mimaya; S Kondo; K Kawa; A Okada; E Hiyama; S Suita; H Takamatsu Journal: Br J Cancer Date: 2002-04-08 Impact factor: 7.640
Authors: Erin K Barr; Kathryn Laurie; Kristen Wroblewski; Mark A Applebaum; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2020-07-25 Impact factor: 3.167
Authors: Mark A Applebaum; Erin K Barr; Jason Karpus; Diana C West-Szymanski; Meritxell Oliva; Elizabeth A Sokol; Sheng Zhang; Zhou Zhang; Wei Zhang; Alexandre Chlenski; Helen R Salwen; Emma Wilkinson; Marija Dobratic; Robert L Grossman; Lucy A Godley; Barbara E Stranger; Chuan He; Susan L Cohn Journal: Clin Cancer Res Date: 2019-12-18 Impact factor: 12.531
Authors: Anoop Mayampurath; Siddhi Ramesh; Diana Michael; Liu Liu; Nicholas Feinberg; Meaghan Granger; Arlene Naranjo; Susan L Cohn; Samuel L Volchenboum; Mark A Applebaum Journal: JCO Clin Cancer Inform Date: 2021-12
Authors: Jianhua Feng; Frankie Wt Cheng; Alex Wk Leung; Vincent Lee; Eva Wm Yeung; Hoi Ching Lam; Jeanny Cheung; Grace Ks Lam; Terry Tw Chow; Carol Ls Yan; Chi Kong Li Journal: Pediatr Investig Date: 2020-09-27
Authors: Brian D Weiss; Gregory Yanik; Arlene Naranjo; Fan F Zhang; Wendy Fitzgerald; Barry L Shulkin; Marguerite T Parisi; Heidi Russell; Stephan Grupp; Luke Pater; Peter Mattei; Yael Mosse; Hollie A Lai; Jason A Jarzembowski; Hiroyuki Shimada; Judith G Villablanca; Roger Giller; Rochelle Bagatell; Julie R Park; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2021-05-24 Impact factor: 3.838
Authors: Angela Bellini; Ulrike Pötschger; Virginie Bernard; Eve Lapouble; Sylvain Baulande; Peter F Ambros; Nathalie Auger; Klaus Beiske; Marie Bernkopf; David R Betts; Jaydutt Bhalshankar; Nick Bown; Katleen de Preter; Nathalie Clément; Valérie Combaret; Jaime Font de Mora; Sally L George; Irene Jiménez; Marta Jeison; Barbara Marques; Tommy Martinsson; Katia Mazzocco; Martina Morini; Annick Mühlethaler-Mottet; Rosa Noguera; Gaelle Pierron; Maria Rossing; Sabine Taschner-Mandl; Nadine Van Roy; Ales Vicha; Louis Chesler; Walentyna Balwierz; Victoria Castel; Martin Elliott; Per Kogner; Geneviève Laureys; Roberto Luksch; Josef Malis; Maja Popovic-Beck; Shifra Ash; Olivier Delattre; Dominique Valteau-Couanet; Deborah A Tweddle; Ruth Ladenstein; Gudrun Schleiermacher Journal: J Clin Oncol Date: 2021-06-11 Impact factor: 50.717
Authors: Gladys G Olivera; Yania Yáñez; Pablo Gargallo; Luis Sendra; Salvador F Aliño; Vanessa Segura; Miguel Ángel Sanz; Adela Cañete; Victoria Castel; Jaime Font De Mora; David Hervás; Pablo Berlanga; María José Herrero Journal: Int J Mol Sci Date: 2020-04-14 Impact factor: 5.923